- Home
- RMTI vs QNTM Comparison
RMTI vs QNTM Comparison
Compare RMTI & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMTI
- QNTM
- Stock Information
- Founded
- RMTI 1994
- QNTM 1998
- Country
- RMTI United States
- QNTM Canada
- Employees
- RMTI N/A
- QNTM N/A
- Industry
- RMTI Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- RMTI Health Care
- QNTM
- Exchange
- RMTI Nasdaq
- QNTM NYSE
- Market Cap
- RMTI 33.0M
- QNTM 35.6M
- IPO Year
- RMTI 1998
- QNTM N/A
- Fundamental
- Price
- RMTI $0.91
- QNTM $35.00
- Analyst Decision
- RMTI Strong Buy
- QNTM
- Analyst Count
- RMTI 2
- QNTM 0
- Target Price
- RMTI $4.00
- QNTM N/A
- AVG Volume (30 Days)
- RMTI 163.6K
- QNTM 341.5K
- Earning Date
- RMTI 08-07-2025
- QNTM 08-13-2025
- Dividend Yield
- RMTI N/A
- QNTM N/A
- EPS Growth
- RMTI N/A
- QNTM N/A
- EPS
- RMTI N/A
- QNTM N/A
- Revenue
- RMTI $97,727,000.00
- QNTM N/A
- Revenue This Year
- RMTI N/A
- QNTM N/A
- Revenue Next Year
- RMTI $11.16
- QNTM N/A
- P/E Ratio
- RMTI N/A
- QNTM N/A
- Revenue Growth
- RMTI 12.82
- QNTM N/A
- 52 Week Low
- RMTI $0.86
- QNTM $2.70
- 52 Week High
- RMTI $5.15
- QNTM $38.25
- Technical
- Relative Strength Index (RSI)
- RMTI 39.80
- QNTM 91.11
- Support Level
- RMTI $0.91
- QNTM $12.75
- Resistance Level
- RMTI $1.00
- QNTM $15.58
- Average True Range (ATR)
- RMTI 0.05
- QNTM 3.10
- MACD
- RMTI -0.00
- QNTM 1.80
- Stochastic Oscillator
- RMTI 11.71
- QNTM 87.25
About RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.